| 产品描述: | TK-129 is an orally active, low-toxicity, potent KDM5B inhibitor (with high affinity; IC50=44 nM). TK-129 exerts cardioprotective effects by inhibiting KDM5B and blocking the KDM5B-associated Wnt pathway. TK-129 reduces ang II-induced activation of cardiac fibroblasts in vitro and reduces isoprenaline-induced myocardial remodelling and fibrosis in vivo. TK-129 can be used in studies of cardiovascular disease. |
| 靶点: |
KDM5:44 nM (IC50) |
| 体外研究: |
TK-129 (2 g/kg; p.o.; single) shows good bio-safety in mice. TK-129 (50 mg/kg; p.o.; twice daily for 24 days) effectively reduces isoproterenol-induced pathological myocardial remodeling in vivo. TK-129 (2 or 10 mg/kg; i.v. or p.o.; single) demonstrates favorable PK properties in vivo. |
| 体内研究: |
TK-129 mediates inhibition of KDM5B activity significantly reduces the activation, migration, and proliferation of myofibroblasts induced by Ang II in vitro. TK-129 (10 μM; 48 h) shows low cytotoxicity in NRCFs and NRCMs. TK-129 (0.1, 0.2, 0.3, 0.4, 0.5 μM; 48 h) can engage toand inhibit KDM5B activity in NRCFs. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.275 ml |
16.373 ml |
32.746 ml |
| 5 mM |
0.655 ml |
3.275 ml |
6.549 ml |
| 10 mM |
0.327 ml |
1.637 ml |
3.275 ml |
| 50 mM |
0.065 ml |
0.327 ml |
0.655 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |